Anika Therapeutics CEO Cheryl Blanchard receives $10M in 2020
Anika Therapeutics reports 2020 executive compensation
By ExecPay News
Published: April 30, 2021
Anika Therapeutics reported fiscal year 2020 executive compensation information on April 30, 2021.
In 2020, seven executives at Anika Therapeutics received on average a compensation package of $2.5M, a 90% increase compared to previous year.
Average pay of disclosed executives at Anika Therapeutics
Cheryl R. Blanchard, Chief Executive Officer, received $10M in total. 53% of Blanchard's compensation, or $5.3M, was in stock awards. Blanchard also received $459K in bonus, $3.7M in option awards, $548K in salary, as well as $28K in other compensation.
Michael L. Levitz, Chief Financial Officer, received a compensation package of $1.9M. 43% of the compensation package, or $800K, was in option awards.
David Colleran, General Counsel, earned $1.7M in 2020.
Sylvia Cheung, Chief Financial Officer, received $1.3M in 2020.
Thomas Finnerty, EVP, Human Resources, earned $1.1M in 2020, a 1% increase compared to previous year.
James Loerop, EVP, Business Development and Strategic Planning, received $1M in 2020, which decreases by 30% compared to 2019.
Joseph G. Darling, Chief Executive Officer, earned $289K in 2020.
Related executives
Thomas Finnerty
Anika Therapeutics
EVP, Human Resources
James Loerop
Anika Therapeutics
EVP, Business Development and Strategic Planning
Joseph Darling
Anika Therapeutics
Chief Executive Officer
Sylvia Cheung
Anika Therapeutics
Chief Financial Officer
Cheryl Blanchard
Anika Therapeutics
Chief Executive Officer
Michael Levitz
Anika Therapeutics
Chief Financial Officer
David Colleran
Anika Therapeutics
General Counsel
You may also like
Source: SEC filing on April 30, 2021.